Search

Your search keyword '"Lee, Esther J."' showing total 4 results
Start Over Author "Lee, Esther J." Publisher elsevier
4 results on '"Lee, Esther J."'

1. Contributors

Author

Ahmed, Syed M., primary, Alexandraki, Irene, additional, Amorosa, Louis F., additional, Anderson, Gregory J., additional, Andrade, Roberto A., additional, Bagley, Bruce, additional, Barrett, Bruce, additional, Basilan, Richard, additional, Beard, J. Mark, additional, Biggs, Wendy S., additional, Bland, Harold, additional, Bober, John F., additional, Brechtelsbauer, David A., additional, Buchanan, Jason N., additional, Buescher, Jennifer J., additional, Cadwallader, Kara, additional, Carroll, William E., additional, Carter, Charles, additional, Comeau, Douglas, additional, Crichlow, Renee, additional, Crouch, Earl R., additional, Crouch, Eric R., additional, David, Alan K., additional, DeGruy, Frank Verloin, additional, Dippel, Eric J., additional, Drezner, Jonathan A., additional, Dupras, Denise M., additional, Ewigman, Bernard, additional, Feero, W. Gregory, additional, Feinstein, Robert E., additional, Foreman, Blair, additional, Garrison, Gregory M., additional, Gingrich, Curtis, additional, Gordon, Andrea, additional, Grant, Thomas R., additional, Guerrera, Mary P., additional, Guirguis-Blake, Janelle, additional, Harmon, Kimberly G., additional, Heaton, Kevin, additional, Heidelbaugh, Joel J., additional, Hensrud, Donald D., additional, Hernandez-Trujillo, Vivian, additional, Herold, Arthur H., additional, Hershberger, Paul J., additional, Holleman, Robert, additional, Holten, Keith B., additional, Holtrop, Jodi Summers, additional, Houston, Thomas, additional, Hutchinson, Mark R., additional, Jonas, Wayne, additional, Kelly, Robert B., additional, Kimmel, Sanford R., additional, Koo, Hoonmo, additional, Kopes-Kerr, Colin P., additional, Kowalhuk, Alicia, additional, Krejci-Manwaring, Jennifer, additional, Lee, Esther J., additional, Lemkau, Jeanne P., additional, Lieberman, Phil, additional, Linares, Adriana C., additional, McBride, David R., additional, McCrary, David, additional, Merry, Stephen P., additional, Meyers, David, additional, Mitchell, Gregg, additional, Moeller, James L., additional, Mooradian, Arshag, additional, Moser, Scott E., additional, Noel, Mary Barth, additional, O'Handley, John G., additional, O'Kane, John W., additional, Osborn, Justin, additional, Paladine, Heather L., additional, Patel, Minal, additional, Pridjian, Gabriella, additional, Rakel, David P., additional, Rakel, Robert E., additional, Rascoe, Terry G., additional, Ratliff-Schaub, Karen, additional, Reed, Brian C., additional, Reis, Michael D., additional, Rindfleisch, J. Adam, additional, Ritter, R. Hal, additional, Roland, William E., additional, Rothberg, Brian, additional, Rust, George, additional, Samiuddin, Zishan, additional, Samraj, Gorge, additional, Schneck, Christopher D., additional, Schrager, Sarina B., additional, Schutt-Ainé, Ann I., additional, Seikel, Stacy, additional, Shah, Ashish R., additional, Shah, Krupa, additional, Shammas, Nicolas W., additional, Sherin, Kevin M., additional, Silverstein, Jeffrey A., additional, Smith, Alan J., additional, Smith, David A., additional, Smucker, Douglas R., additional, Snavely, Abby, additional, Stallworth, James, additional, Stevens, Nancy G., additional, Stiles, Melissa, additional, Strauch, Elizabeth M., additional, Susman, Jeff, additional, Swee, David, additional, Thompson, Margaret, additional, Tobin, Evan J., additional, Toth, Peter P., additional, Usatine, Richard P., additional, Wadland, William C., additional, Waldren, Steven, additional, Walsh, Kathleen, additional, Warner, Elizabeth A., additional, Westney, Gloria, additional, White, Russell D., additional, Williams, Dave E., additional, Wilson, George, additional, Wilson, Jane E., additional, Wolff, Tracy, additional, Zazove, Philip, additional, and Zeimet, Anthony, additional

Published
2011
Full Text
View/download PDF

3. Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials.

Author

Gabrielson AT, Daniels MJ, Rowe J, Alam R, Lee EJ, Matoso A, De Felice A, Hahn N, Hoffman-Censits J, Bivalacqua TJ, and Kates M

Subjects
Chemotherapy, Adjuvant, Cystectomy, Disease Progression, Female, Humans, Male, Muscles pathology, Neoadjuvant Therapy adverse effects, Retrospective Studies, Urinary Bladder pathology, Carcinoma in Situ drug therapy, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms surgery
Abstract

Purpose: To better define surrogate endpoints for neoadjuvant chemotherapy (NAC) trials in patients with muscle-invasive bladder cancer. We compared survival in patients with carcinoma in-situ (CIS) only vs. complete response following NAC and radical cystectomy (RC)., Materials and Methods: Patients with cT2-4N0M0 disease treated with NAC and RC between 2001 and 2018 were stratified by response: complete response (CR, pT0N0), partial response (PR, pTaN0, pT1N0+/-CIS), CIS-only (pTisN0), stable disease (SD, pT2N0), or progressive disease (PD, >pT2N0). Primary endpoints were overall survival (OS) and risk of recurrence in patients with CIS-only vs. CR. Multivariable Cox proportional hazards regression model was used for OS and a competing risks proportional hazards model was used for risk of recurrence., Results: Of 1,406 patients in our institution cohort, 340 patients met inclusion criteria. Kaplan-Meier mean estimates of OS for CR and CIS-only were 108.9 months (95% CI 89.7-127.9) and 125.8 months (95% CI 112.3-139.3), respectively (P = 0.13). Cox proportional hazards model found no difference in OS between patients with PR (HR 1.06, 95% CI 0.33-2.58, P = 0.897) or CIS-only (HR 0.422, 95% CI 0.15-1.18, P = 0.101) when compared to CR. The risk of recurrence was similar between patients with CIS-only (HR 0.73, 95% 0.29-1.84, P = 0.49) and PR (HR 1.32, 95% CI 0.54-3.29, P = 0.54) when compared to CR on competing risks analysis., Conclusions: Residual CIS-only after NAC and RC demonstrated similar survival outcomes when compared to patients with pathologic CR. Further study in large multi-institutional cohorts may further validate CIS-only as an additional surrogate endpoint after NAC and may inform future trials., Competing Interests: Conflict of interest The authors declared no conflict interests., (Copyright © 2021 Elsevier Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

4. Synthetic biodegradable hydrogel delivery of demineralized bone matrix for bone augmentation in a rat model.

Author

Kinard LA, Dahlin RL, Lam J, Lu S, Lee EJ, Kasper FK, and Mikos AG

Subjects
Alkaline Phosphatase metabolism, Animals, Bone and Bones diagnostic imaging, Bone and Bones drug effects, Compressive Strength drug effects, Disease Models, Animal, Fumarates chemistry, Male, Materials Testing, Mice, Osteogenesis drug effects, Polyethylene Glycols chemistry, Rats, Inbred F344, X-Ray Microtomography, Biocompatible Materials pharmacology, Bone Matrix chemistry, Hydrogel, Polyethylene Glycol Dimethacrylate pharmacology, Orthopedic Procedures methods
Abstract

There exists a strong clinical need for a more capable and robust method to achieve bone augmentation, and a system with fine-tuned delivery of demineralized bone matrix (DBM) has the potential to meet that need. As such, the objective of the present study was to investigate a synthetic biodegradable hydrogel for the delivery of DBM for bone augmentation in a rat model. Oligo(poly(ethylene glycol) fumarate) (OPF) constructs were designed and fabricated by varying the content of rat-derived DBM particles (either 1:3, 1:1 or 3:1 DBM:OPF weight ratio on a dry basis) and using two DBM particle size ranges (50-150 or 150-250 μm). The physical properties of the constructs and the bioactivity of the DBM were evaluated. Selected formulations (1:1 and 3:1 with 50-150 μm DBM) were evaluated in vivo compared to an empty control to investigate the effect of DBM dose and construct properties on bone augmentation. Overall, 3:1 constructs with higher DBM content achieved the greatest volume of bone augmentation, exceeding 1:1 constructs and empty implants by 3- and 5-fold, respectively. As such, we have established that a synthetic, biodegradable hydrogel can function as a carrier for DBM, and that the volume of bone augmentation achieved by the constructs correlates directly to the DBM dose., (Copyright © 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results